EFFECT OF ISRADIPINE ON RENAL HEMODYNAMICS AND SYSTEMIC BLOOD-PRESSURE CHANGES INDUCED BY INTRAVENOUS-INFUSION OF ENDOTHELIN IN HEALTHY HUMANS

Citation
Ss. Sorensen et al., EFFECT OF ISRADIPINE ON RENAL HEMODYNAMICS AND SYSTEMIC BLOOD-PRESSURE CHANGES INDUCED BY INTRAVENOUS-INFUSION OF ENDOTHELIN IN HEALTHY HUMANS, Nephrology, dialysis, transplantation, 10(8), 1995, pp. 1324-1331
Citations number
34
Categorie Soggetti
Urology & Nephrology",Transplantation
ISSN journal
09310509
Volume
10
Issue
8
Year of publication
1995
Pages
1324 - 1331
Database
ISI
SICI code
0931-0509(1995)10:8<1324:EOIORH>2.0.ZU;2-X
Abstract
Background. In some vascular beds calcium-channel-blocking agents have been shown to posses some antagonism to endothelin-1 (ET-1)-induced v asoconstriction. This issue has not been well investigated in humans, however. Methods. The study had a double-blind cross-over design. In 1 2 healthy human volunteers we investigated the effect of pretreatment with either isradipine 10 mg daily for 1 week or placebo on changes in (i) systemic and renal haemodynamics and (ii) renal handling of sodiu m and water induced by intravenous infusion of ET-1 at a rate of 1 pmo l/min/kg for 60 min. Results. Infusion of ET-1 affected systemic haemo dynamics. The increase in diastolic blood pressure was similar after p retreatment with placebo (+6.8%) or isradipine (+5.3%). The changes in renal haemodynamics in response to ET-1 infusion were also familiar, e.g. renal plasma flow (-32.1% versus -31.2%), glomerular filtration r ate (-8.8% versus -10.9%) and renal vascular resistance (+55.1% versus +52.7%). Likewise the changes in renal handling of sodium and water i n response to ET-1 infusion were unaffected by pretreatment with place bo or isradipine, e.g. sodium excretion (-44.6% versus -40.8%), urine flow rate (-49.8% Versus -38.9%) and clearance of lithium (-32.0% vers us -29.1%). Conclusions. Intravenous infusion of ET-1 in healthy human s discretely increases diastolic blood pressure and profoundly decreas es renal haemodynamics and excretion of sodium and water. Pretreatment with the calcium-channel blocking agent isradipine for 1 week in a cl inically relevant dose does not interfere with the action of ET-1.